Table 1.
Multivariable Analyses of OS and EFS of Patients With AML From Validation Sets*
| Variable | HR | 95% CI | P |
|---|---|---|---|
| OS | |||
| Netherlands Set 2 (n = 277) | |||
| 24-gene signature: high v low | 1.9 | 1.4 to 2.9 | < .001 |
| KRAS mutation v wild type | 92.2 | 23.9 to 356.3 | < .001 |
| Complex v others | 3.8 | 2.2 to 6.4 | < .001 |
| FLT3-ITD v others | 1.4 | 1.0 to 2.1 | .04 |
| t(8;21) v others | 0.4 | 0.1 to 1.0 | .04 |
| Age group: ≥ 60 v < 60 years | 2.1 | 1.5 to 2.9 | < .001 |
| Germany Set 2 (n = 548) | |||
| 24-gene signature: high v low | 1.4 | 1.1 to 1.8 | .002 |
| FLT3-ITD v others | 1.5 | 1.2 to 1.9 | < .001 |
| inv(16) v others | 0.3 | 0.2 to 0.6 | < .001 |
| t(15;17) v others | 0.4 | 0.2 to 0.6 | < .001 |
| Complex v others | 2.1 | 1.5 to 2.9 | < .001 |
| Age group: ≥ 60 v < 60 years | 1.7 | 1.4 to 2.1 | < .001 |
| t-AML v others | 2.8 | 1.3 to 6.1 | .01 |
| EFS | |||
| Netherlands Set 2 (n = 277) | |||
| 24-gene signature: high v low | 1.7 | 1.2 to 2.2 | .001 |
| KRAS mutation v wild type | 87.3 | 23.2 to 328.3 | < .001 |
| Complex v others | 3.0 | 1.8 to 4.8 | < .001 |
| t(15;17) v others | 3.1 | 1.6 to 5.9 | < .001 |
| t(8;21) v others | 0.4 | 0.2 to 0.9 | .04 |
| del(3q) v others | 2.1 | 1.1 to 4.0 | .03 |
| Age group: ≥ 60 v < 60 years | 1.8 | 1.3 to 2.5 | < .001 |
| Germany Set 2 (n = 548) | |||
| 24-gene signature: high v low | 1.4 | 1.1 to 1.7 | .005 |
| NPM1 mutation v wild type | 0.5 | 0.4 to 0.7 | < .001 |
| FLT3-ITD v others | 1.6 | 1.3 to 2.1 | < .001 |
| inv(16) v others | 0.4 | 0.2 to 0.7 | .002 |
| −7/del(7q) v others | 2.1 | 1.2 to 3.6 | .01 |
| inv(3)/t(3;3) v others | 3.0 | 1.6 to 5.4 | < .001 |
| Complex v others | 2.2 | 1.6 to 3.0 | < .001 |
| Age group: ≥ 60 v < 60 years | 1.5 | 1.3 to 1.9 | < .001 |
| t-AML v others | 2.9 | 1.4 to 6.0 | .005 |
NOTE. The following variables were evaluated in univariable Cox regression models for outcome: sum-value signature, age, sex, platelet count, WBC, percentage of blood blasts, percentage of bone marrow blasts, presence or absence of various chromosomal translocations [ie, inv(16), t(8;21), t(15;17), t(9;11), t(11q23), t(6;9), t(9;22)] or other abnormalities [+8, −3/inv(3q)/t(3;3), −7/del(7q)], and presence or absence of gene mutations (ie, FLT3-ITD, FLT3-TKD, NRAS, KRAS, NPM1, CEBPA, MLL-PTD). Variables for which P < .1 in univariable models (Data Supplement) were included in multivariable analysis for sum-value signature. Only variables for which P < .05 in multivariable models are shown in Table. HRs > 1 or < 1 indicate, respectively, higher or lower risk of event for higher values of continuous variables and for first category listed for categorical variables in OS or EFS models.
Abbreviations: AML, acute myeloid leukemia; EFS, event-free survival; HR, hazard ratio; ITD, internal tandem duplication; OS, overall survival; PTD, partial tandem duplication; t-AML, therapy-related AML; TKD, tyrosine kinase domain.